Hi all. Just wanted to congratulate all the long-time holders of TapImmune and thank the board (mostly Phantom Lord) for some good info. I’ve been researching the company since it popped on my radar in May, and I started a position when it dropped at the end of July. To be honest, I wouldn’t be here if it wasn’t for the CEO and the merger with Marker Therapeutics, and the all-star Scientific Advisory Board.
Also wanted to recognize the 1 year anniversary today of the hire of the CEO, Peter Hoang. I believe with his venture capital and investment banking background, and his knowledge of CAR-T and immunotherapy, he will (as we are seeing already) completely transform this company. He understands the technology and what needs to be done to bring it to market. Not sure if this was posted here but, he was offered the CEO position at ViraCyte by John Wilson (Marker CEO) last year, but instead took the job at TapImmune. I think when when he got a look at Marker’s platform last summer, he was very interested and found a way to bring them public, and TapImmune shareholders are the beneficiaries of this brilliant move. And BTW - I wouldn’t be at all surprised if ViraCyte is also brought into the fold at some point in the near future.
Moving the headquarters to the Biotech hub in Houston is a smart move as well as reincorporating in Delaware. There is a good reason most Fortune 500 companies are incorporated in Delaware. Their laws tends to protect the rights of boards of directors and shareholders, (vs. Nevada which protects management) and has an excellent body of corporate case law regarding such matters as management/shareholder issues and mergers & acquisitions. So by reincorporating in Delaware, it shows that Hoang is already looking to attract VC investors and planning to grow the company to become a Fortune 500 company.
I received my proxy materials in the mail today and voted HELL YES to all. (But to be honest - on PROP 8, I’m not sure about Marcum LLP )
